However, NSCLC patients with a high tumor PD-L1 expression (i.e., their tumor proportion score [TPS]) and/or a high PD-L1 expression in tumor-infiltrating immune cells (i.e., their combined positive score [CPS]) benefit more from a single-agent immunotherapy compared to the previous standard-of-care platinum-based chemotherapy [131,132,133]. This evidence concerns the gene CD274 and neoplasm.